Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2021
- Last Action
- 5/19/2021
Actions
- 2021-05-19Read twice and referred to the Committee on Finance.
- 2021-05-19Introduced in Senate
CRS Summary
As of 2021-05-19 (00)
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2021
This bill modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports.
Additionally, the Centers for Medicare & Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices.
Subjects
- Aging
- Congressional oversight
- Health care costs and insurance
- Health care quality
- Health information and medical records
- Health promotion and preventive care
- Medical tests and diagnostic methods
- Medicare
- Neurological disorders
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.